For many the question has not been if, but when will biopharma step into medical cannabis. A recently published article delved into that question and the conclusion could perhaps best be summarized in one word, now.  According to the authors, leading biopharma’s Sanofi (38), Pfizer (4), AstraZeneca (2) and GSK (1) have cannabis related clinical trials registered with the FDA. However, perhaps a far more important indicator of what lies ahead for biopharma’s role in cannabis, is the number of cannabis patents. Leading the list is Abbvie (59), Sanofi (39), Merck (35). BMS (34), Pfizer (25), Novartis (21), Roche (17) and the list goes on. Learn More